US20090048318A1
(en)
*
|
2003-04-29 |
2009-02-19 |
Connie Erickson-Miller |
Methods for treating degenerative diseases/injuries
|
US20070105824A1
(en)
*
|
2003-04-29 |
2007-05-10 |
Erickson-Miller Connie L |
Methods for treating degenerative diseases/injuries
|
US20090143453A1
(en)
*
|
2003-04-29 |
2009-06-04 |
Connie Erickson-Miller |
Methods for treating degenerative diseases/injuries
|
US20090298179A1
(en)
*
|
2003-04-29 |
2009-12-03 |
Connie Erickson-Miller |
Methods For Treating Degenerative Diseases/Injuries
|
FR2871158A1
(fr)
|
2004-06-04 |
2005-12-09 |
Aventis Pharma Sa |
Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
|
FR2888579A1
(fr)
*
|
2005-07-13 |
2007-01-19 |
Aventis Pharma Sa |
Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation
|
PE20061119A1
(es)
*
|
2005-01-19 |
2006-11-27 |
Aventis Pharma Sa |
PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
|
FR2889526B1
(fr)
|
2005-08-04 |
2012-02-17 |
Aventis Pharma Sa |
7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
|
CA2621261C
(en)
|
2005-09-22 |
2014-05-20 |
Incyte Corporation |
Azepine inhibitors of janus kinases
|
US7625890B2
(en)
*
|
2005-11-10 |
2009-12-01 |
Smithkline Beecham Corp. |
Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
|
GB0525164D0
(en)
|
2005-12-09 |
2006-01-18 |
Xention Discovery Ltd |
Compounds
|
DK2343299T3
(en)
|
2005-12-13 |
2016-01-18 |
Incyte Holdings Corp |
Heteroberl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
|
WO2007078340A2
(en)
|
2005-12-30 |
2007-07-12 |
Anacor Pharmaceuticals, Inc. |
Boron-containing small molecules
|
CN102532180B
(zh)
*
|
2005-12-30 |
2016-06-29 |
安纳考尔医药公司 |
含硼的小分子
|
WO2007105657A1
(ja)
*
|
2006-03-10 |
2007-09-20 |
Kyoto University |
クロスカップリング反応を用いたオリゴマー化合物の合成方法
|
MX2008012482A
(es)
*
|
2006-03-31 |
2008-10-10 |
Abbott Lab |
Compuestos de indazol.
|
LT2010528T
(lt)
|
2006-04-19 |
2017-12-27 |
Novartis Ag |
6-o-pakeistieji benzoksazolo junginiai bei csf-1r signalo perdavimo slopinimo būdai
|
JP4862994B2
(ja)
*
|
2006-04-26 |
2012-01-25 |
日産化学工業株式会社 |
2−(2−ヒドロキシエトキシ)イソインドリン−1,3−ジオン化合物の選択的製造方法
|
US20110053931A1
(en)
*
|
2006-06-08 |
2011-03-03 |
John Gaudino |
Quinoline compounds and methods of use
|
EP2113500A1
(en)
|
2006-10-31 |
2009-11-04 |
Takeda Pharmaceutical Company Limited |
MAPK/ERK kinase inhibitors
|
ES2415863T3
(es)
|
2006-12-22 |
2013-07-29 |
Incyte Corporation |
Heterociclos sustituidos como inhibidores de Janus Quinasas
|
JP2008174495A
(ja)
*
|
2007-01-19 |
2008-07-31 |
Reverse Proteomics Research Institute Co Ltd |
創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
ES2575797T3
(es)
|
2007-06-13 |
2016-07-01 |
Incyte Holdings Corporation |
Sales del inhibidor de cinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
SI2215094T1
(sl)
|
2007-11-15 |
2016-05-31 |
Ym Biosciences Australia Pty Ltd |
N vsebujoče heterociklične spojine
|
EP2070929A1
(en)
|
2007-12-11 |
2009-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
|
WO2009085185A1
(en)
|
2007-12-19 |
2009-07-09 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
PT2288610T
(pt)
|
2008-03-11 |
2016-10-17 |
Incyte Holdings Corp |
Derivados de azetidina e de ciclobutano como inibidores de jak
|
JP5530422B2
(ja)
*
|
2008-04-07 |
2014-06-25 |
アムジエン・インコーポレーテツド |
細胞周期阻害薬としてのgem−二置換およびスピロ環式アミノピリジン/ピリミジン
|
PE20110223A1
(es)
|
2008-06-10 |
2011-05-07 |
Abbvie Inc |
DERIVADOS DE PIRROLO[2,3-e][1,2,4]TRIAZOLO[4,3-a]PIRAZIN, COMO INHIBIDORES DE QUINASA
|
UA103195C2
(uk)
|
2008-08-11 |
2013-09-25 |
Глаксосмитклайн Ллк |
Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
|
EP2432555B1
(en)
|
2009-05-22 |
2014-04-30 |
Incyte Corporation |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
DK2432472T3
(da)
|
2009-05-22 |
2019-11-18 |
Incyte Holdings Corp |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
|
CN104945420A
(zh)
|
2009-06-29 |
2015-09-30 |
因塞特公司 |
作为pi3k抑制剂的嘧啶酮类
|
US8796297B2
(en)
|
2009-06-30 |
2014-08-05 |
Abbvie Inc. |
4-substituted-2-amino-pyrimidine derivatives
|
CN105037355B
(zh)
|
2009-08-10 |
2017-06-06 |
萨穆梅德有限公司 |
Wnt信号传导途径的吲唑抑制剂及其治疗用途
|
WO2011019780A1
(en)
|
2009-08-11 |
2011-02-17 |
Bristol-Myers Squibb Company |
Azaindazoles as btk kinase modulators and use thereof
|
US9249145B2
(en)
|
2009-09-01 |
2016-02-02 |
Incyte Holdings Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
US9340555B2
(en)
|
2009-09-03 |
2016-05-17 |
Allergan, Inc. |
Compounds as tyrosine kinase modulators
|
KR20120082890A
(ko)
*
|
2009-09-03 |
2012-07-24 |
알러간, 인코포레이티드 |
타이로신 카이네이스 조절체로서 화합물
|
CA2777114C
(en)
|
2009-10-09 |
2018-10-23 |
Incyte Corporation |
Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
PE20121336A1
(es)
|
2009-12-01 |
2012-11-03 |
Abbvie Inc |
Nuevos compuestos triciclicos
|
AU2010326030A1
(en)
*
|
2009-12-01 |
2012-06-07 |
Abbvie Inc. |
Novel tricyclic compounds
|
US8680108B2
(en)
*
|
2009-12-18 |
2014-03-25 |
Incyte Corporation |
Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
SI3001903T1
(en)
|
2009-12-21 |
2018-02-28 |
Samumed, Llc |
1H-pyrazolo (3,4-b) pyridines and their therapeutic uses
|
US8378104B2
(en)
|
2010-02-11 |
2013-02-19 |
OSI Pharmaceuticals, LLC |
7-aminofuropyridine derivatives
|
MX364636B
(es)
|
2010-03-10 |
2019-05-03 |
Incyte Corp |
Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
|
CN104710385B
(zh)
|
2010-03-12 |
2018-11-09 |
奥默罗斯公司 |
Pde10抑制剂以及相关组合物和方法
|
BR112012024380A2
(pt)
|
2010-03-25 |
2015-09-15 |
Glaxosmithkline Llc |
compostos químicos
|
UY33288A
(es)
*
|
2010-03-25 |
2011-10-31 |
Glaxosmithkline Llc |
Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
|
WO2011130342A1
(en)
|
2010-04-14 |
2011-10-20 |
Incyte Corporation |
FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
|
EP3087972A1
(en)
|
2010-05-21 |
2016-11-02 |
Incyte Holdings Corporation |
Topical formulation for a jak inhibitor
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
WO2012036919A2
(en)
*
|
2010-09-14 |
2012-03-22 |
Glaxosmithkline Llc |
Combination of braf and vegf inhibitors
|
AU2011329734B2
(en)
|
2010-11-19 |
2015-05-28 |
Incyte Holdings Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
JP5917544B2
(ja)
|
2010-11-19 |
2016-05-18 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
|
WO2012087881A1
(en)
|
2010-12-20 |
2012-06-28 |
Incyte Corporation |
N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
|
BR112013020798B1
(pt)
|
2011-02-18 |
2022-03-15 |
Incyte Corporation |
Uso e composição contendo uma combinação de um inibidor mtor e de um inibidor de jak para tratamento de neoplasisas mieloproliferativas
|
US9108984B2
(en)
|
2011-03-14 |
2015-08-18 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
|
MY161199A
(en)
|
2011-03-23 |
2017-04-14 |
Amgen Inc |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
WO2012135009A1
(en)
|
2011-03-25 |
2012-10-04 |
Incyte Corporation |
Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
|
CA3042808A1
(en)
*
|
2011-04-12 |
2012-10-18 |
Moerae Matrix, Inc. |
Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
|
US9890200B2
(en)
|
2011-04-12 |
2018-02-13 |
Moerae Matrix, Inc. |
Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
|
KR20140040819A
(ko)
|
2011-06-20 |
2014-04-03 |
인사이트 코포레이션 |
Jak 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
|
WO2013014052A1
(en)
|
2011-07-22 |
2013-01-31 |
Glaxosmithkline Llc |
Composition
|
CA2844507A1
(en)
|
2011-08-10 |
2013-02-14 |
Novartis Pharma Ag |
Jak pi3k/mtor combination therapy
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
PE20181272A1
(es)
|
2011-09-02 |
2018-08-03 |
Incyte Holdings Corp |
Heterociclilaminas como inhibidores de pi3k
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
BR112014006127A2
(pt)
|
2011-09-14 |
2017-04-04 |
Samumed Llc |
indazol-3-carboxamidas e sua utilização como inibidores da via de sinalização wnt/b-catenina
|
KR20130083772A
(ko)
*
|
2012-01-13 |
2013-07-23 |
주식회사 엘지생활건강 |
피부 주름 개선 및 탄력 증진용 조성물
|
US9493481B2
(en)
|
2012-02-23 |
2016-11-15 |
Vanderbilt University |
Substituted 5-aminothieno[2,3—C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
MA37577B1
(fr)
|
2012-05-04 |
2018-05-31 |
Samumed Llc |
1h-pyrazolo[3,4-b]pyridines et leurs utilisations thérapeutiques
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
WO2013188528A1
(en)
*
|
2012-06-13 |
2013-12-19 |
Fred Hutchinson Cancer Research Center |
Compositions comprising chalcogenides and related methods
|
WO2014009219A1
(en)
*
|
2012-07-10 |
2014-01-16 |
Bayer Pharma Aktiengesellschaft |
Method for preparing substituted triazolopyridines
|
UA114109C2
(xx)
|
2012-08-24 |
2017-04-25 |
|
Піразолопіримідинові сполуки
|
EP2903615B1
(en)
*
|
2012-10-05 |
2021-04-07 |
Merck Sharp & Dohme Corp. |
5-pyridin-3-yl-2,3-dihydro-1h-indole derivatives as aldosterone synthase (cyp11b2) inhibitors for the treatment of hypertension
|
EP2911655A1
(en)
|
2012-10-24 |
2015-09-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival
|
WO2014072881A1
(en)
*
|
2012-11-08 |
2014-05-15 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
EP3949953A1
(en)
|
2012-11-15 |
2022-02-09 |
Incyte Holdings Corporation |
Sustained-release dosage forms of ruxolitinib
|
EP2922550B1
(en)
|
2012-11-20 |
2017-04-19 |
Glaxosmithkline LLC |
Novel compounds
|
ES2625023T3
(es)
|
2012-11-20 |
2017-07-18 |
Glaxosmithkline Llc |
Compuestos novedosos
|
PT2922549T
(pt)
|
2012-11-20 |
2017-09-01 |
Glaxosmithkline Llc |
Novos compostos
|
CN105120862A
(zh)
|
2013-01-08 |
2015-12-02 |
萨穆梅德有限公司 |
Wnt信号途径的3-(苯并咪唑-2-基)-吲唑抑制剂及其治疗应用
|
EP3489239B1
(en)
|
2013-03-06 |
2021-09-15 |
Incyte Holdings Corporation |
Processes and intermediates for making a jak inhibitor
|
CA2901267C
(en)
*
|
2013-04-04 |
2021-01-19 |
Janssen Pharmaceutica Nv |
Novel n-(2,3-dihydro-1h-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and n-(2,3-dihydro-1h-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors
|
EP3003369A4
(en)
*
|
2013-05-28 |
2017-04-26 |
Momenta Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising pyrophosphate
|
PT3030227T
(pt)
|
2013-08-07 |
2020-06-25 |
Incyte Corp |
Formas de dosagem de libertação prolongada para um inibidor de jak1
|
US9637498B2
(en)
|
2013-08-23 |
2017-05-02 |
Vanderbilt University |
Substituted thieno[2,3-C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
|
BR112016023623A2
(pt)
*
|
2014-04-25 |
2017-08-15 |
Pfizer |
compostos heteroaromáticos e seu uso como ligantes de dopamina d1
|
NZ716494A
(en)
|
2014-04-28 |
2017-07-28 |
Omeros Corp |
Processes and intermediates for the preparation of a pde10 inhibitor
|
NZ630803A
(en)
|
2014-04-28 |
2016-03-31 |
Omeros Corp |
Optically active pde10 inhibitor
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
EP3154954B1
(en)
*
|
2014-06-10 |
2022-02-09 |
Sanford-Burnham Medical Research Institute |
Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
|
US10077277B2
(en)
|
2014-06-11 |
2018-09-18 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
|
WO2016040182A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
|
WO2016040188A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040181A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040184A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040180A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040190A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
WO2016040193A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
WO2016040185A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
|
US10106554B2
(en)
|
2014-12-11 |
2018-10-23 |
Natco Pharma Limited |
7-(morpholinyl)-2-(N-piperazinyl) methyl thieno [2, 3-C] pyridine derivatives as anticancer drugs
|
RS63963B1
(sr)
|
2015-02-27 |
2023-03-31 |
Incyte Holdings Corp |
Postupak pripreme pi3k inhibitora
|
CN104829629B
(zh)
*
|
2015-03-26 |
2017-03-15 |
天津药物研究院有限公司 |
含磺酰胺基的四氢噻吩并[2,3‑c]吡啶衍生物、其制备方法和用途
|
RU2017134509A
(ru)
|
2015-04-24 |
2019-04-04 |
Омерос Корпорейшн |
Ингибиторы pde10 и соответствующие композиции и способы
|
US9732097B2
(en)
|
2015-05-11 |
2017-08-15 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
WO2016183063A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Crystalline forms of a pi3k inhibitor
|
CN107922428B
(zh)
*
|
2015-06-25 |
2021-02-05 |
普洛麦格公司 |
噻吩并吡咯化合物及其作为刺虾源性荧光素酶的抑制剂的用途
|
US10350199B2
(en)
|
2015-08-03 |
2019-07-16 |
Samumed, Llc |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
US10195185B2
(en)
|
2015-08-03 |
2019-02-05 |
Samumed, Llc |
3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017024004A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10285982B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
US10519169B2
(en)
|
2015-08-03 |
2019-12-31 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
US10392383B2
(en)
|
2015-08-03 |
2019-08-27 |
Samumed, Llc |
3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10463651B2
(en)
|
2015-08-03 |
2019-11-05 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
|
US10188634B2
(en)
|
2015-08-03 |
2019-01-29 |
Samumed, Llc |
3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017023984A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
US10166218B2
(en)
|
2015-08-03 |
2019-01-01 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
WO2017023987A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
US10285983B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
|
US10329309B2
(en)
|
2015-08-03 |
2019-06-25 |
Samumed, Llc |
3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017024003A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017023986A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
|
US10383861B2
(en)
|
2015-08-03 |
2019-08-20 |
Sammumed, LLC |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
US10226453B2
(en)
|
2015-08-03 |
2019-03-12 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
US11524964B2
(en)
|
2015-10-16 |
2022-12-13 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11512092B2
(en)
|
2015-10-16 |
2022-11-29 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
AU2016340167B2
(en)
|
2015-10-16 |
2021-06-24 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
US11773106B2
(en)
|
2015-10-16 |
2023-10-03 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
JP2018535969A
(ja)
|
2015-11-04 |
2018-12-06 |
オメロス コーポレーション |
Pde10阻害剤の固体状態形態
|
JP6982748B2
(ja)
|
2015-11-06 |
2021-12-17 |
バイオスプライス セラピューティクス インコーポレイテッド |
2−(1H−インダゾール−3−イル)−3H−イミダゾ[4,5−c]ピリジンおよびそれらの抗炎症的使用
|
WO2017156398A1
(en)
*
|
2016-03-10 |
2017-09-14 |
Assia Chemical Industries Ltd. |
Solid state forms of venetoclax and processes for preparation of venetoclax
|
WO2017207387A1
(en)
|
2016-05-31 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
|
HUE060797T2
(hu)
|
2016-06-01 |
2023-04-28 |
Biosplice Therapeutics Inc |
Eljárás N-(5-(3-(7-(3-fluorfenil)-3H-imidazo[4,5-c]piridin-2-il)-1H-indazol-5-il)- piridin-3-il)-3-metilbutánamid elõállítására
|
US10154992B2
(en)
*
|
2016-07-12 |
2018-12-18 |
The Regents Of The University Of California |
Compounds and methods for treating HIV infection
|
WO2018024602A1
(en)
|
2016-08-04 |
2018-02-08 |
Bayer Aktiengesellschaft |
2,7-diazaspiro[4.4]nonanes
|
KR102493364B1
(ko)
*
|
2016-09-14 |
2023-01-27 |
얀센 파마슈티카 엔.브이. |
Menin-mll 상호작용의 융합 바이사이클릭 억제제
|
BR112019004691A2
(pt)
|
2016-09-14 |
2019-06-25 |
Janssen Pharmaceutica Nv |
inibidores bicíclicos em espiro da interação menina-mll
|
AU2017345699A1
(en)
|
2016-10-21 |
2019-05-16 |
Samumed, Llc |
Methods of using indazole-3-carboxamides and their use as Wnt/B-catenin signaling pathway inhibitors
|
MA46696A
(fr)
|
2016-11-07 |
2019-09-11 |
Samumed Llc |
Formulations injectables à dose unique prêtes à l'emploi
|
JP7142010B2
(ja)
|
2016-12-15 |
2022-09-26 |
ヤンセン ファーマシューティカ エヌ.ベー. |
メニン-mll相互作用のアゼパン阻害剤
|
US10815247B2
(en)
|
2016-12-28 |
2020-10-27 |
Promega Corporation |
Functionalized NANOLUC inhibitors
|
TW201840318A
(zh)
|
2017-03-09 |
2018-11-16 |
美商艾伯維有限公司 |
治療克羅恩氏病和潰瘍性結腸炎之方法
|
US11564922B2
(en)
|
2017-03-09 |
2023-01-31 |
Abbvie Inc. |
Methods of treating crohn's disease and ulcerative colitis
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
US11396517B1
(en)
|
2017-12-20 |
2022-07-26 |
Janssen Pharmaceutica Nv |
Exo-aza spiro inhibitors of menin-MLL interaction
|
CN108047087B
(zh)
*
|
2018-01-18 |
2020-06-05 |
河南省科学院化学研究所有限公司 |
3’-(4-溴萘-1-基)[1,1’-联苯基]-4-腈及其合成方法
|
AR114810A1
(es)
|
2018-01-30 |
2020-10-21 |
Incyte Corp |
Procesos e intermedios para elaborar un inhibidor de jak
|
MX2022012285A
(es)
|
2018-03-30 |
2023-08-15 |
Incyte Corp |
Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
|
SG11202009438UA
(en)
|
2018-04-18 |
2020-11-27 |
Constellation Pharmaceuticals Inc |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
CA3100977A1
(en)
|
2018-05-21 |
2019-11-28 |
Constellation Pharmaceuticals, Inc. |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
US11560388B2
(en)
|
2019-03-19 |
2023-01-24 |
Boehringer Ingelheim Vetmedica Gmbh |
Anthelmintic aza-benzothiophene and aza-benzofuran compounds
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
WO2021257857A1
(en)
|
2020-06-19 |
2021-12-23 |
Incyte Corporation |
Naphthyridinone compounds as jak2 v617f inhibitors
|
WO2021257863A1
(en)
|
2020-06-19 |
2021-12-23 |
Incyte Corporation |
Pyrrolotriazine compounds as jak2 v617f inhibitors
|
US11767323B2
(en)
|
2020-07-02 |
2023-09-26 |
Incyte Corporation |
Tricyclic pyridone compounds as JAK2 V617F inhibitors
|
AU2021300429A1
(en)
|
2020-07-02 |
2023-02-16 |
Incyte Corporation |
Tricyclic urea compounds as JAK2 V617F inhibitors
|
WO2022046989A1
(en)
|
2020-08-27 |
2022-03-03 |
Incyte Corporation |
Tricyclic urea compounds as jak2 v617f inhibitors
|
US11919908B2
(en)
|
2020-12-21 |
2024-03-05 |
Incyte Corporation |
Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
|